{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:11Z","timestamp":1791648431548,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies (ADTs), particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort analysis used data from the Medical Data Vision database, including patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD) who had initiated UST therapy. Cumulative UST continuation rates and factors associated with UST failure were analyzed, and post hoc subgroup analyses based on prior ADT use were conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1971 patients with CD and 1284 patients with UC were included. Overall, the concomitant use of 5-ASA did not significantly affect UST failure in either CD or UC. Post hoc subgroup analysis suggested a protective effect of 5-ASA in ADT-na\u00efve patients with CD or UC who had been previously exposed to ADT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>5-ASA did not provide a significant overall benefit when used in combination with UST for CD or UC. However, post hoc subgroup analyses indicated a potential role for 5-ASA in specific subgroups. Further studies are necessary to confirm these findings and explore personalized treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaf001","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T23:10:36Z","timestamp":1736723436000},"page":"2373-2380","source":"Crossref","is-referenced-by-count":10,"title":["Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-5059","authenticated-orcid":false,"given":"Yu","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-5672","authenticated-orcid":false,"given":"Shuhei","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ominami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nadatani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusei","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"issue":"7152","key":"2025092307420317900_CIT0001","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature."},{"issue":"14","key":"2025092307420317900_CIT0002","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med."},{"issue":"20","key":"2025092307420317900_CIT0003","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"16","key":"2025092307420317900_CIT0004","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"issue":"13","key":"2025092307420317900_CIT0005","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"2025092307420317900_CIT0006","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-aminosalicylate medication use in patients with Crohn\u2019s disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025092307420317900_CIT0007","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/apt.15771","article-title":"Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease","volume":"52","author":"Chapman","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2025092307420317900_CIT0008","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","article-title":"AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology."},{"issue":"2","key":"2025092307420317900_CIT0009","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn\u2019s disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol."},{"issue":"6","key":"2025092307420317900_CIT0010","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut."},{"issue":"5","key":"2025092307420317900_CIT0011","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cgh.2019.08.012","article-title":"Stopping mesalamine therapy in patients with Crohn\u2019s disease starting biologic therapy does not increase risk of adverse outcomes","volume":"18","author":"Ungaro","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"2025092307420317900_CIT0012","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/ecco-jcc\/jjad113","article-title":"Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease: post hoc analyses of clinical trial data","volume":"17","author":"Ungaro","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2025092307420317900_CIT0013","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41395-018-0144-2","article-title":"No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2025092307420317900_CIT0014","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jgh.15838","article-title":"No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: a territory-wide population-based study","volume":"37","author":"Mak","year":"2022","journal-title":"J Gastroenterol Hepatol."},{"key":"2025092307420317900_CIT0015","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16786","article-title":"Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis","author":"Nishida","year":"2024","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"2025092307420317900_CIT0016","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025092307420317900_CIT0017","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2025092307420317900_CIT0018","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn\u2019s disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025092307420317900_CIT0019","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/s1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn\u2019s disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2025092307420317900_CIT0020","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-c","article-title":"Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Pentasa Crohn\u2019s Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology."},{"issue":"1","key":"2025092307420317900_CIT0021","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025092307420317900_CIT0022","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025092307420317900_CIT0023","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology."},{"issue":"9","key":"2025092307420317900_CIT0024","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/apt.14023","article-title":"Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease","volume":"45","author":"Bonovas","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2025092307420317900_CIT0025","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/ajg.2012.198","article-title":"5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations","volume":"107","author":"Nguyen","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"28","key":"2025092307420317900_CIT0026","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.3748\/wjg.14.4434","article-title":"Molecular basis of the potential of mesalazine to prevent colorectal cancer","volume":"14","author":"Stolfi","year":"2008","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2025092307420317900_CIT0027","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10620-018-5378-8","article-title":"Effect of long-term mesalamine therapy on cancer-associated gene expression in colonic mucosa of patients with ulcerative colitis","volume":"64","author":"Bajpai","year":"2019","journal-title":"Dig Dis Sci."},{"issue":"12","key":"2025092307420317900_CIT0028","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1940-6207.CAPR-16-0124","article-title":"Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management","volume":"9","author":"Dulai","year":"2016","journal-title":"Cancer Prev Res (Phila)."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf001\/61424545\/izaf001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/9\/2373\/61424545\/izaf001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/9\/2373\/61424545\/izaf001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:44:40Z","timestamp":1758627880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/9\/2373\/7952825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf001","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,1,11]]}}}